TO THE EDITOR
Gemtuzumab ozogamicin (Mylotarg) is a humanized anti-CD33 monoclonal antibody conjugated to a potent antitumor antibiotic calicheamicin. 1 Since its approval by Food Drug Administration (FDA) in 2000, it has been increasing used to treat elderly patients who have refractory or relapsed acute myeloblastic leukemia (AML) with an overall complete remission rate of 30%. 2 In a phase II clinical trial on safety and efficacy, gemtuzumab is shown to cause prolonged thrombocytopenia in 13% patients who have otherwise achieved complete hematological remission, and some of these patients died of fatal intracranial hemorrhage. 2 The causes of thrombocytopenia have not been fully elucidated. We reported a patient whose clinicopathologic picture might shed light on the mechanism of thrombocytopenia after treatment with gemtuzumab. 3 Mr RC was a 72-year-old retired architect with good past health who was admitted to Queen Mary Hospital, Hong Kong on Nov 8, 2004, because of symptomatic anemia. At presentation, his peripheral blood film showed leucoerythroblastic blood picture with hemoglobin 5.8 g/dl, total white cell 1.5 Â 10 9 /l, absolute neutrophil 0, and platelet 16 Â 10 9 /l. Bone marrow aspirate showed AML with multi-lineage dysplasia, with prominent dyserythropoiesis and dysmegakaryopoiesis ( Figure 1 ). Two doses of gemtuzumab (9 mg/m 2 /dose) were given 2 weeks apart as salvage therapy. At 30 days after the first dose of gemtuzumab, the absolute neutrophil count increased precipitously back to normal level. No colonystimulating factors or buffy coat has been given throughout the course. A bone marrow aspirate performed 5 weeks after the first dose of gemtuzumab showed good morphological remission with plentiful megakaryocytes of normal morphology and blast count was not increased. However, the patient remained thrombocytopenic despite repeated platelet transfusions. These observations suggested a peripheral cause of thrombocytopenia and led us to treat him with intravenous immunoglobulin (IVIG, 0.5 g/kg/day) for five days as a salvage therapy. At 3 days after commencement of IVIG therapy, the platelet count rose precipitously to above 100 Â 10 9 /l without transfusion, and within a week the platelet count has remained above 300 Â 10 9 /l. Results from this patient demonstrated a possible immune cause of thrombocytopenia after treatment of gemtuzumab. The initial thrombocytopenia at presentation is part of the manifestation of acute myeloid leukemia with dysmegakaryopoiesis. Gemtuzumab treatment led to good disease control, as shown by the recovery of absolute neutrophil count and a morphological remission marrow with decrease in blast population and active and mature granulopoiesis. Remarkably, the platelet count remained extremely low and the marrow showed increased megakaryocytes, mostly of normal morphology. The clinicopathologic picture led us to suspect a possible immune cause of thrombocytopenia. This proposition is supported by the swift response and the complete recovery of platelet counts after IVIG treatment.
The cause of persistent thrombocytopenia in AML patients who otherwise showed complete bone marrow remission after gemtuzumab treatment has not been elucidated. Myelotoxicity of gemtuzumab is often linked to its antiproliferative and cytotoxic effects on normal CD33 hematopoietic progenitors. However, only a small minority of megakaryocytes expresses CD33, suggesting that other mechanisms might account for the phenomenon of prolonged thrombocytopenia. Although gemtuzumab has not been shown to induce antiplatelet antibodies, the platelet recovery after IVIG in this patient may suggest a yet uncharacterized immune-mediated process. IVIG is widely used in patients with autoimmune thrombocytopenic purpura by blockade of the Fc receptors in macrophages, thereby reducing clearance of antibody-coated platelets. Whether a similar mechanism might operate in this patient is presently unclear. 4 This report might therefore provide ground of research into the cause of thrombocytopenia after gemtuzumab treatment. The translocation t(11;14) involving immunoglobulin heavychain gene switch region and cylin D1 is the most common IgH translocation (15-20%) in multiple myeloma (MM). 1,2 MM patients with t(11;14) are considered in some studies to have a better prognosis when treated with either conventional chemotherapy or autologous stem cell transplant. 3, 4 In contrast, patients with chromosome 13q deletions (40-50%) have a poor prognosis.
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5-7 These results would predict that long-term survivors of MM would more frequently harbor a t(11;14) but not a 13q deletions. To address this, we used cytoplasmic Igenhanced fluorescence in situ hybridization (cIg-FISH) to evaluate clonal plasma cells for t(11;14) and 13q status from 20 long-term survivor MM cases.
All of these patients met the diagnostic criteria for MM before May 1995 and have survived greater than or equal to 8 years from diagnosis at the time of analysis. The 11 male and nine female had a median age of 52 years (range 39-62 years), with a median bone marrow plasmacytosis of 30% (range, 10-80%) at diagnosis. None of these cases had smoldering myeloma or MGUS using standard definitions. In all, 11 had IgG, six IgA, two free light chains and one nonsecretory. Of the 20 patients, 17 received autologous stem cell transplantation. The median duration between diagnosis to transplant was 24 months (range 5-149 months), and the median progression-free survival (PFS) after transplant was 32 months (range, 1-62 months). One patient died 3 years after transplant and 10 years after diagnosis. The other 19 patients remain alive.
We used cIg-FISH with a fusion strategy for detection of t(11;14). The IgH probe labeled with SpectrumGreen and the cyclin D1 probe labeled with SpectrumRed were obtained from Vysis (Downers, Grove, IL, USA). A patient was considered to have t(11;14) if the percent of clonal plasma cells exceeded 10% of signals with a abnormal pattern (fusions) indicative of a t(11;14). All of the cases were also tested for chromosome 13q status using the probes LSI CEP8 and D13S319 as described previously.
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Of the 20 cases, t(11;14) was detected in only one patient with 94% clonal plasma cells involved. This patient who had PFS of 20 months after autologous stem cell transplant and is alive B3 years post-transplant and 10.5 years after initial diagnosis. Chromosome 13q deletions were found in three cases (15%), with a median of 43% clonal plasma cells involved. All three patients are alive.
Since only one (5%) of the long-term MM survivors harbored t(11;14), this study argues against a major role of t(11;14) in prolonging the survival of these MM patients. Hence, despite its association with a better prognosis, our results suggest that t(11;14) should not be used as a predictor for long-term survivors in MM. As anticipated, 13q deletions were infrequent in this group of MM. 
